U.S. federal trademark · Serial No. 98311406
Monoclonal antibodies used in industry and science, and in the manufacture of pharmaceuticals, pharmaceutical preparations and substances, for the treatment of immune-excluded tumors found in recalcitrant cancers
Drug discovery services for the discovery of monoclonal antibody-containing drugs for the treatment of immune-excluded tumors, provided through a computational platform engine using biology and chemistry analytics in the field of recalcitrant cancers
Monoclonal antibody products and preparations for the treatment of immune-excluded tumors found in recalcitrant cancers; pharmaceutical products and preparations consisting of monoclonal antibodies for the treatment of immune-excluded tumors found in recalcitrant cancers; pharmaceutical preparations developed with a computational platform engine using biology and chemistry analytics for the treatment of immune-excluded tumors found in recalcitrant cancers
Source: USPTO federal trademark records. Informational only, not legal advice. Status and details may lag the live USPTO database.